JW Pharmaceutical Corporation (KRX:001060)
South Korea · Delayed Price · Currency is KRW 26,300
+600 (2.33%)
Last updated: Aug 11, 2026, 1:09 PM KST
JW Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 586,794 | 584,933 | 561,695 | 828,523 | 419,688 | 505,678 | |
Market Cap Growth | 14.44% | 4.14% | -32.20% | 97.41% | -17.00% | -32.85% |
Enterprise Value | 574,600 | 571,085 | 600,784 | 959,912 | 491,395 | 649,827 |
Last Close Price | 25700.00 | 24967.90 | 23499.20 | 34154.17 | 17093.97 | 20225.75 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.28 | 9.65 | 8.64 | 22.39 | 13.16 | - |
Forward PE | - | 6.18 | 6.50 | 14.34 | 10.40 | 26.79 |
PS Ratio | 0.74 | 0.75 | 0.78 | 1.11 | 0.61 | 0.83 |
PB Ratio | 1.54 | 1.58 | 1.71 | 3.12 | 1.86 | 2.68 |
P/TBV Ratio | 1.59 | 1.64 | 1.76 | 3.29 | 1.84 | 2.68 |
P/FCF Ratio | 7.87 | 6.91 | 7.90 | 13.84 | 8.96 | 47.45 |
P/OCF Ratio | 6.88 | 6.07 | 7.08 | 9.51 | 7.39 | 27.90 |
PEG Ratio | - | 0.17 | 0.17 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.73 | 0.74 | 0.84 | 1.28 | 0.72 | 1.07 |
EV/EBITDA Ratio | 4.76 | 5.36 | 5.90 | 8.05 | 6.36 | 13.84 |
EV/EBIT Ratio | 5.65 | 6.50 | 7.26 | 9.93 | 8.12 | 21.07 |
EV/FCF Ratio | 7.70 | 6.75 | 8.45 | 16.03 | 10.49 | 60.98 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.14 | 0.15 | 0.28 | 0.64 | 0.93 | 1.30 |
Debt / EBITDA Ratio | 0.46 | 0.51 | 0.90 | 1.43 | 2.71 | 5.22 |
Debt / FCF Ratio | 0.73 | 0.65 | 1.29 | 2.84 | 4.47 | 23.00 |
Net Debt / Equity Ratio | -0.03 | -0.02 | 0.18 | 0.29 | 0.27 | 0.95 |
Net Debt / EBITDA Ratio | -0.10 | -0.06 | 0.58 | 0.64 | 0.77 | 3.82 |
Net Debt / FCF Ratio | -0.16 | -0.08 | 0.83 | 1.27 | 1.28 | 16.84 |
Asset Turnover | 1.28 | 1.28 | 1.15 | 1.18 | 1.09 | 1.03 |
Inventory Turnover | 3.52 | 3.75 | 3.64 | 3.79 | 3.70 | 3.65 |
Quick Ratio | 0.86 | 0.86 | 0.82 | 0.90 | 0.80 | 0.79 |
Current Ratio | 1.46 | 1.42 | 1.47 | 1.32 | 1.12 | 1.30 |
Return on Equity (ROE) | 20.07% | 17.60% | 21.87% | 15.65% | 14.41% | -0.73% |
Return on Assets (ROA) | 10.08% | 9.08% | 8.28% | 9.49% | 6.00% | 3.26% |
Return on Invested Capital (ROIC) | 19.20% | 16.20% | 17.88% | 21.60% | 12.18% | -0.62% |
Return on Capital Employed (ROCE) | 24.20% | 22.20% | 20.90% | 27.00% | 24.40% | 8.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 11.73% | 10.52% | 11.58% | 4.47% | 7.60% | -0.19% |
FCF Yield | 12.71% | 14.47% | 12.65% | 7.23% | 11.16% | 2.11% |
Payout Ratio | 15.47% | 17.99% | 14.86% | 23.82% | 23.05% | - |
Buyback Yield / Dilution | 10.87% | 7.88% | -3.34% | -2.49% | -0.07% | 0.05% |
Total Shareholder Return | 13.54% | 7.88% | -3.34% | -2.49% | -0.07% | 0.05% |